Investigational Ganaxolone in the Treatment of Refractory Seizure Disorders
Monday, December 6, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
Visitors to this Scientific Exhibit will learn about Marinus' current findings of ganaxolone in the treatment of rare acute and chronic seizure disorders, the Marinus research pipeline, and Marinus' goals in treating refractory seizures.
Exhibitor: Marinus Pharmaceuticals, Inc.
Activity Type
Scientific Exhibit
Credit
Non-CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Scientists/Researchers
Advanced Practice Providers
Advocates
Pharmacists
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals